APA (7th ed.) Citation

Strober, B., Thaçi, D., Sofen, H., Kircik, L., Gordon, K. B., Foley, P., . . . Papp, K. A. (2023). Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. Journal of the American Academy of Dermatology, 88(1), 40-51. https://doi.org/10.1016/j.jaad.2022.08.061

Chicago Style (17th ed.) Citation

Strober, Bruce, et al. "Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Phase 3 Program FOr Evaluation Of TYK2 Inhibitor Psoriasis Second Trial." Journal of the American Academy of Dermatology 88, no. 1 (2023): 40-51. https://doi.org/10.1016/j.jaad.2022.08.061.

MLA (9th ed.) Citation

Strober, Bruce, et al. "Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Phase 3 Program FOr Evaluation Of TYK2 Inhibitor Psoriasis Second Trial." Journal of the American Academy of Dermatology, vol. 88, no. 1, 2023, pp. 40-51, https://doi.org/10.1016/j.jaad.2022.08.061.